Bolt Biotherapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 21, 2024. Bolt is a clinical-stage biopharmaceutical company developing cancer immunotherapies. It has no approved products and has not generated product sales.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Collaboration revenue | $7.9 million | $5.7 million |
| Research and development expense | $61.5 million | $73.1 million |
| General and administrative expense | $22.5 million | $22.9 million |
| Operating loss | $76.2 million | $90.3 million |
| Interest income | $7.0 million | $2.2 million |
| Net loss | $69.2 million | $88.1 million |
| Net loss per share, basic and diluted | $1.83 | $2.36 |
| Net cash used in operating activities | $69.5 million | $76.5 million |
Collaboration revenue came from Toray, Genmab and Innovent; there was no product revenue. Operating and profit margins are not meaningful indicators for this pre-commercial company, which reported operating and net losses.
At year-end, cash, cash equivalents and marketable securities totaled $128.6 million; cash and cash equivalents were $10.8 million, and short- and long-term investments were $117.8 million. Total assets were $159.8 million, total liabilities $47.0 million, and stockholders’ equity $112.7 million. Accumulated deficit was $364.3 million. The filing reports no outstanding borrowings; operating lease liabilities totaled $20.2 million. Management said available cash and investments were expected to fund operations for at least 12 months after filing, while also stating that additional capital will be needed to advance programs.
Material changes and business developments
- Revenue rose $2.1 million year over year, primarily from continued Genmab and Innovent collaboration work.
- Net loss narrowed by $18.9 million. R&D expense fell $11.6 million, mainly because of lower manufacturing costs and lab and contract-service expenses; interest income increased $4.8 million with higher yields.
- Trastuzumab imbotolimod (formerly BDC-1001) completed Phase 1 and advanced to Phase 2 studies in HER2-positive colorectal, endometrial, gastroesophageal and metastatic breast cancers. FDA granted orphan drug designation for gastric cancer, including gastroesophageal junction cancer.
- Phase 1 enrolled 131 patients across 16 HER2-expressing tumor types. At the selected recommended Phase 2 dose of 20 mg/kg every other week, the filing reports a 29% response rate among evaluable HER2-positive patients in each arm (2/7 monotherapy and 2/7 with nivolumab). The small evaluable groups limit interpretation. Drug-related grade 3-or-higher adverse events occurred in 7.6% of subjects; no grade 5 drug-related events were reported.
- BDC-3042 received FDA IND clearance in July 2023; the first patient was dosed in a Phase 1 study in October. The first three dose cohorts were completed without dose-limiting toxicities.
- After year-end, in March 2024, Bolt amended its Innovent collaboration to obtain worldwide rights to two ISAC programs, assume future development costs, and receive a one-time $4.7 million payment; Innovent is eligible for sales milestones and royalties. This is a subsequent event, not a 2023 operating result.
Outlook, risks and unusual items
Management expects continued losses and significant R&D spending, including clinical-trial and manufacturing costs. The filing provides no revenue or earnings guidance. Funding needs depend on trial progress, costs, collaborations and financing conditions; new equity could dilute stockholders, while partnering could require granting rights.
- Development and regulatory outcomes remain uncertain: both lead programs are early-stage, and no candidate has completed a pivotal trial or received marketing approval. Clinical results to date do not establish future efficacy or safety.
- Bolt relies on third parties for manufacturing and clinical-trial services, including single-source suppliers in some cases. Supply, quality, scale-up or vendor disruptions could delay development.
- The company reported $128.6 million in cash, cash equivalents and marketable securities at year-end, but stated that it will need additional capital to continue advancing programs.
- Federal and state NOL carryforwards were $205.7 million and $278.5 million, respectively; management expects Section 382 limits to cause approximately $2.8 million of federal R&D credits and $51.0 million of California NOLs to expire unused.
- The filing identifies macroeconomic, geopolitical, competitive, reimbursement, intellectual-property and data-security risks. No pending legal matter was identified as likely to have a material adverse effect.
- Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor gave an unqualified opinion on the financial statements, but did not audit internal control effectiveness.
Key facts investors should verify
- Whether the Phase 2 trastuzumab imbotolimod trials confirm meaningful, durable efficacy in the intended tumor types, with larger patient groups and acceptable safety.
- Enrollment, dose escalation, safety and emerging clinical data for BDC-3042.
- Actual cash use and financing runway against management’s 12-month estimate, including the funding implications of taking on two Innovent programs.
- Manufacturing capacity, supplier continuity and clinical-trial execution as programs advance.
- Terms, development obligations and potential economics of collaboration and licensing arrangements, including the March 2024 Innovent amendment.
- Potential dilution from future capital raises and the effect of stock-based compensation; 10.7 million options were outstanding at year-end.